歐羅拉專利離子通道閱讀器 ICR

離子通道藥物的細胞模型高通量篩選

HTS for Ion channel drug research

制藥行業的關注焦點，從藥物原料問題向藥物研發早期中對藥物安全性評估的轉變，催生了藥物研發早期對于離子通道篩選的需要，而且這種需要越來越受到制藥行業的關注。例如，藥物引起的QT間期延長以及心率失常，已經促使相關藥物安全性評估法例的出臺，例如S7B、E14指導文件。藥物研發早期對于類似潛在風險的評估，將有助于藥物研發企業集中精力在已通過毒性評估可以上市的藥物上，避免將時間資源投放在不能通過測試的藥品，降低企業研發成本。新的離子通道篩選技術以及資源有望徹底改變市場，有望降低藥物研發的瓶頸，增大開發力度。隨著藥物專利的開放，以及藥廠努力尋找新的治療方案，自動化的解決方案更能為此類需要的企業降低費用，提高藥物研發以及安全性評估效率。

利用我們優勢的儀器，創造性地利用活體細胞進行高通量分析（cold flux assays）

應用

ICR 8000和ICR 12000可應用在以下的離子通道研究：

Aurora公司的離子通道閱讀器技術不僅可應用于在細胞水平表達的離子通道靶點，也可應用在合成小泡中表達的離子轉運通道或者孔形成蛋白。

?

如何給歐羅拉留言？

歡迎點擊【一鍵咨詢】，【發送留言】后我們會馬上聯系您，為您的實驗或應用需求推薦合適的儀器配置

?

Assay Services

Aurora Biomed?provides functional assay services on an exclusive, out-sourced basis.??
We are currently carrying out assay services for various ion channel targets including hERG safety screen. Several options for these services exist, we can read/test flux assay samples from your experiments on ICR, we can screen your compounds/library in our laboratories or we can accept cell lines to develop assay for you as part of our services.

Aurora Biomed has a team of highly trained molecular biologists have a solid understanding of ion channels and flux assays. We enjoy a challenge and feel confident in providing solutions to further your ion channel screening needs.

We are pleased to offer both?cold flux assays?using our proprietary Ion Channel Reader technology and?manual voltage-clamp electrophysiology?assays.?

Cold flux assays?utilize tracer ions to study the ion channel of interest.? The method of detection for Aurora Biomed’s cold flux assays is flame atomic absorption spectroscopy as employed by our proprietary Ion Channel Reader technology.? The Ion Channel Reader Series provides a high throughput format for ion channel screening by the flux assay approach.? The use of high throughput assays helps reduce the burden on electrophysiology by providing some idea of which compounds should be screened if resources are limited and not all compounds can be screened with manual-patch clamp.? The cold flux assay approach is ideal for determining which compounds to follow up with electrophysiology as there is a strong linear correlation (R=0.88) and consistently identical drug rank orders between the two methods.

Manual voltage-clamp electrophysiology?is the gold-standard for ion channel screening.? Moreover, the FDA requires?in vitro?electrophysiology studies in conjunction with?in vivo?studies for compounds submitted for NDA status.? Oocyte-based studies assess potential cellular mechanisms that may not be evident from?in vivo?data.

The ICR 12000 designed for ultra high throughput screening of compound libraries against ion channel targets. Based on the robustness of Aurora Biomed's ICR technology, the reader offers high sensitivity generating accurate drug rank order matching electrophysiology data. This new member of the ICR series provides the throughput to access compound QT liability early in the drug discovery process.

給我們留言或致電，我們會為您推薦介紹